1. ShinHR, LeeCU, ParkHJ, SeolSY, ChungJM, et al. (1996) Hepatitis B and C virus, Clonorchis sinensis for the risk of liver cancer: a case-control study in Pusan, Korea. International journal of epidemiology 25: 933–940.
2. WatanapaP (1996) Cholangiocarcinoma in patients with opisthorchiasis. The British journal of surgery 83: 1062–1064.
3. WatanapaP, WatanapaWB (2002) Liver fluke-associated cholangiocarcinoma. The British journal of surgery 89: 962–970.
4. BergquistA, EkbomA, OlssonR, KornfeldtD, LoofL, et al. (2002) Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. Journal of hepatology 36: 321–327.
5. BergquistA, GlaumannH, PerssonB, BroomeU (1998) Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis: a case-control study. Hepatology 27: 311–316.
6. BurakK, AnguloP, PashaTM, EganK, PetzJ, et al. (2004) Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. The American journal of gastroenterology 99: 523–526.
7. ClaessenMM, VleggaarFP, TytgatKM, SiersemaPD, van BuurenHR (2009) High lifetime risk of cancer in primary sclerosing cholangitis. Journal of hepatology 50: 158–164.
8. VisserBC, SuhI, WayLW, KangSM (2004) Congenital choledochal cysts in adults. Archives of surgery 139: 855–860 discussion 860–852.
9. HsingAW, ZhangM, RashidA, McGlynnKA, WangBS, et al. (2008) Hepatitis B and C virus infection and the risk of biliary tract cancer: a population-based study in China. International journal of cancer Journal international du cancer 122: 1849–1853.
10. KobayashiM, IkedaK, SaitohS, SuzukiF, TsubotaA, et al. (2000) Incidence of primary cholangiocellular carcinoma of the liver in japanese patients with hepatitis C virus-related cirrhosis. Cancer 88: 2471–2477.
11. LiuXF, ZouSQ, QiuFZ (2003) Pathogenesis of cholangiocarcinoma in the porta hepatis and infection of hepatitis virus. Hepatobiliary & pancreatic diseases international : HBPD INT 2: 285–289.
12. ShaibYH, El-SeragHB, DavilaJA, MorganR, McGlynnKA (2005) Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. Gastroenterology 128: 620–626.
13. WelzelTM, GraubardBI, El-SeragHB, ShaibYH, HsingAW, et al. (2007) Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 5: 1221–1228.
14. YamamotoS, KuboS, HaiS, UenishiT, YamamotoT, et al. (2004) Hepatitis C virus infection as a likely etiology of intrahepatic cholangiocarcinoma. Cancer science 95: 592–595.
15. DonatoF, GelattiU, TaggerA, FavretM, RiberoML, et al. (2001) Intrahepatic cholangiocarcinoma and hepatitis C and B virus infection, alcohol intake, and hepatolithiasis: a case-control study in Italy. Cancer causes & control : CCC 12: 959–964.
16. LeeCC, WuCY, ChenGH (2002) What is the impact of coexistence of hepatolithiasis on cholangiocarcinoma? Journal of gastroenterology and hepatology 17: 1015–1020.
17. BeckerN, LiebermannD, WeschH, Van KaickG (2008) Mortality among Thorotrast-exposed patients and an unexposed comparison group in the German Thorotrast study. European journal of cancer 44: 1259–1268.
18. TravisLB, HauptmannM, GaulLK, StormHH, GoldmanMB, et al. (2003) Site-specific cancer incidence and mortality after cerebral angiography with radioactive thorotrast. Radiation research 160: 691–706.
19. KhanSA, ThomasHC, DavidsonBR, Taylor-RobinsonSD (2005) Cholangiocarcinoma. Lancet 366: 1303–1314.
20. ValleJ, WasanH, PalmerDH, CunninghamD, AnthoneyA, et al. (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. The New England journal of medicine 362: 1273–1281.
21. KibaT, TsudaH, PairojkulC, InoueS, SugimuraT, et al. (1993) Mutations of the p53 tumor suppressor gene and the ras gene family in intrahepatic cholangiocellular carcinomas in Japan and Thailand. Molecular carcinogenesis 8: 312–318.
22. OhashiK, TsutsumiM, NakajimaY, NoguchiO, OkitaS, et al. (1994) High rates of Ki-ras point mutation in both intra- and extra-hepatic cholangiocarcinomas. Japanese journal of clinical oncology 24: 305–310.
23. PetmitrS, PinlaorS, ThousungnoenA, KaralakA, MigasenaP (1998) K-ras oncogene and p53 gene mutations in cholangiocarcinoma from Thai patients. The Southeast Asian journal of tropical medicine and public health 29: 71–75.
24. RoaJC, RoaI, de AretxabalaX, MeloA, FariaG, et al. (2004) [K-ras gene mutation in gallbladder carcinoma]. Revista medica de Chile 132: 955–960.
25. SturmPD, BaasIO, ClementMJ, NakeebA, JohanG, et al. (1998) Alterations of the p53 tumor-suppressor gene and K-ras oncogene in perihilar cholangiocarcinomas from a high-incidence area. International journal of cancer Journal international du cancer 78: 695–698.
26. TadaM, OmataM, OhtoM (1990) Analysis of ras gene mutations in human hepatic malignant tumors by polymerase chain reaction and direct sequencing. Cancer research 50: 1121–1124.
27. TadaM, OmataM, OhtoM (1990) [Detection of ras gene mutations of primary hepatic malignant tumors by polymerase chain reaction and direct sequencing method]. Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology 87: 811–815.
28. TadaM, OmataM, OhtoM (1992) High incidence of ras gene mutation in intrahepatic cholangiocarcinoma. Cancer 69: 1115–1118.
29. WattanasirichaigoonS, TasanakhajornU, JesadapatarakulS (1998) The incidence of K-ras codon 12 mutations in cholangiocarcinoma detected by polymerase chain reaction technique. Journal of the Medical Association of Thailand = Chotmaihet thangphaet 81: 316–323.
30. BobergKM, SchrumpfE, BergquistA, BroomeU, ParesA, et al. (2000) Cholangiocarcinoma in primary sclerosing cholangitis: K-ras mutations and Tp53 dysfunction are implicated in the neoplastic development. Journal of hepatology 32: 374–380.
31. TannapfelA, WeinansL, GeisslerF, SchutzA, KatalinicA, et al. (2000) Mutations of p53 tumor suppressor gene, apoptosis, and proliferation in intrahepatic cholangiocellular carcinoma of the liver. Digestive diseases and sciences 45: 317–324.
32. TulloA, D'ErchiaAM, HondaK, KellyMD, HabibNA, et al. (2000) New p53 mutations in hilar cholangiocarcinoma. European journal of clinical investigation 30: 798–803.
33. HahnSA, BartschD, SchroersA, GalehdariH, BeckerM, et al. (1998) Mutations of the DPC4/Smad4 gene in biliary tract carcinoma. Cancer research 58: 1124–1126.
34. Iacobuzio-DonahueCA, SongJ, ParmiagianiG, YeoCJ, HrubanRH, et al. (2004) Missense mutations of MADH4: characterization of the mutational hot spot and functional consequences in human tumors. Clinical cancer research : an official journal of the American Association for Cancer Research 10: 1597–1604.
35. AhrendtSA, EisenbergerCF, YipL, RashidA, ChowJT, et al. (1999) Chromosome 9p21 loss and p16 inactivation in primary sclerosing cholangitis-associated cholangiocarcinoma. The Journal of surgical research 84: 88–93.
36. TadokoroH, ShigiharaT, IkedaT, TakaseM, SuyamaM (2007) Two distinct pathways of p16 gene inactivation in gallbladder cancer. World journal of gastroenterology : WJG 13: 6396–6403.
37. TaniaiM, HiguchiH, BurgartLJ, GoresGJ (2002) p16INK4a promoter mutations are frequent in primary sclerosing cholangitis (PSC) and PSC-associated cholangiocarcinoma. Gastroenterology 123: 1090–1098.
38. TannapfelA, BenickeM, KatalinicA, UhlmannD, KockerlingF, et al. (2000) Frequency of p16(INK4A) alterations and K-ras mutations in intrahepatic cholangiocarcinoma of the liver. Gut 47: 721–727.
39. YoshidaS, TodorokiT, IchikawaY, HanaiS, SuzukiH, et al. (1995) Mutations of p16Ink4/CDKN2 and p15Ink4B/MTS2 genes in biliary tract cancers. Cancer research 55: 2756–2760.
40. BorgerDR, TanabeKK, FanKC, LopezHU, FantinVR, et al. (2012) Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. The oncologist 17: 72–79.
41. KippBR, VossJS, KerrSE, Barr FritcherEG, GrahamRP, et al. (2012) Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma. Human pathology 43: 1552–1558.
42. GuTL, DengX, HuangF, TuckerM, CrosbyK, et al. (2011) Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma. PloS one 6: e15640.
43. GwakGY, YoonJH, ShinCM, AhnYJ, ChungJK, et al. (2005) Detection of response-predicting mutations in the kinase domain of the epidermal growth factor receptor gene in cholangiocarcinomas. Journal of cancer research and clinical oncology 131: 649–652.
44. LeoneF, CavalloniG, PignochinoY, SarottoI, FerrarisR, et al. (2006) Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research 12: 1680–1685.
45. TannapfelA, SommererF, BenickeM, KatalinicA, UhlmannD, et al. (2003) Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut 52: 706–712.
46. DeshpandeV, NduagubaA, ZimmermanSM, KehoeSM, MacconaillLE, et al. (2011) Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma. BMC cancer 11: 60.
47. RienerMO, BawohlM, ClavienPA, JochumW (2008) Rare PIK3CA hotspot mutations in carcinomas of the biliary tract. Genes, chromosomes & cancer 47: 363–367.
48. WendumD, BarbuV, RosmorducO, ArriveL, FlejouJF, et al. (2012) Aspects of liver pathology in adult patients with MDR3/ABCB4 gene mutations. Virchows Archiv : an international journal of pathology 460: 291–298.
49. ScheimannAO, StrautnieksSS, KniselyAS, ByrneJA, ThompsonRJ, et al. (2007) Mutations in bile salt export pump (ABCB11) in two children with progressive familial intrahepatic cholestasis and cholangiocarcinoma. The Journal of pediatrics 150: 556–559.
50. StrautnieksSS, ByrneJA, PawlikowskaL, CebecauerovaD, RaynerA, et al. (2008) Severe bile salt export pump deficiency: 82 different ABCB11 mutations in 109 families. Gastroenterology 134: 1203–1214.
51. EndoK, AshidaK, MiyakeN, TeradaT (2001) E-cadherin gene mutations in human intrahepatic cholangiocarcinoma. The Journal of pathology 193: 310–317.
52. UkitaY, KatoM, TeradaT (2002) Gene amplification and mRNA and protein overexpression of c-erbB-2 (HER-2/neu) in human intrahepatic cholangiocarcinoma as detected by fluorescence in situ hybridization, in situ hybridization, and immunohistochemistry. Journal of hepatology 36: 780–785.
53. AraiY, TotokiY, HosodaF, ShirotaT, HamaN, et al. (2013) FGFR2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. Hepatology 2013 Oct 9 doi:10.1002/hep.26890. [Epub ahead of print]
54. WuYM, SuF, Kalyana-SundaramS, KhazanovN, AteeqB, et al. (2013) Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov 3: 636–647.
55. NgPC, HenikoffS (2001) Predicting deleterious amino acid substitutions. Genome Res 11: 863–874.
56. AdzhubeiIA, SchmidtS, PeshkinL, RamenskyVE, GerasimovaA, et al. (2010) A method and server for predicting damaging missense mutations. Nat Methods 7: 248–249.
57. RevaB, AntipinY, SanderC (2007) Determinants of protein function revealed by combinatorial entropy optimization. Genome Biol 8: R232.
58. SchwarzJM, RodelspergerC, SchuelkeM, SeelowD (2010) MutationTaster evaluates disease-causing potential of sequence alterations. Nat Methods 7: 575–576.
59. CraigDW, O'ShaughnessyJA, KieferJA, AldrichJ, SinariS, et al. (2013) Genome and transcriptome sequencing in prospective metastatic triple-negative breast cancer uncovers therapeutic vulnerabilities. Mol Cancer Ther 12: 104–116.
60. CirulliV, YebraM (2007) Netrins: beyond the brain. Nat Rev Mol Cell Biol 8: 296–306.
61. QiJH, EbrahemQ, MooreN, MurphyG, Claesson-WelshL, et al. (2003) A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat Med 9: 407–415.
62. SalvucciO, TosatoG (2012) Essential roles of EphB receptors and EphrinB ligands in endothelial cell function and angiogenesis. Adv Cancer Res 114: 21–57.
63. CavallaroU, ChristoforiG (2004) Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat Rev Cancer 4: 118–132.
64. KrausMR, ClauinS, PfisterY, Di MaioM, UlinskiT, et al. (2012) Two mutations in human BICC1 resulting in Wnt pathway hyperactivity associated with cystic renal dysplasia. Hum Mutat 33: 86–90.
65. WangX, OsadaT, WangY, YuL, SakakuraK, et al. (2010) CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer. J Natl Cancer Inst 102: 1496–1512.
66. KrzeslakA, FormaE, BernaciakM, RomanowiczH, BrysM (2012) Gene expression of O-GlcNAc cycling enzymes in human breast cancers. Clin Exp Med 12: 61–65.
67. AntonescuCR, ZhangL, NielsenGP, RosenbergAE, Dal CinP, et al. (2011) Consistent t(1;10) with rearrangements of TGFBR3 and MGEA5 in both myxoinflammatory fibroblastic sarcoma and hemosiderotic fibrolipomatous tumor. Genes Chromosomes Cancer 50: 757–764.
68. HallorKH, SciotR, StaafJ, HeidenbladM, RydholmA, et al. (2009) Two genetic pathways, t(1;10) and amplification of 3p11-12, in myxoinflammatory fibroblastic sarcoma, haemosiderotic fibrolipomatous tumour, and morphologically similar lesions. J Pathol 217: 716–727.
69. KumarR, CrouthamelMC, RomingerDH, GontarekRR, TumminoPJ, et al. (2009) Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors. Br J Cancer 101: 1717–1723.
70. HaGH, ParkJS, BreuerEK (2013) TACC3 promotes epithelial-mesenchymal transition (EMT) through the activation of PI3K/Akt and ERK signaling pathways. Cancer Lett 332: 63–73.
71. TurnerN, GroseR (2010) Fibroblast growth factor signalling: from development to cancer. Nature reviews Cancer 10: 116–129.
72. WilliamsSV, HurstCD, KnowlesMA (2012) Oncogenic FGFR3 gene fusions in bladder cancer. Human molecular genetics. Hum Mol Genet 22: 795–803.
73. MaedaT, YagasakiF, IshikawaM, TakahashiN, BesshoM (2005) Transforming property of TEL-FGFR3 mediated through PI3-K in a T-cell lymphoma that subsequently progressed to AML. Blood 105: 2115–2123.
74. RenM, QinH, RenR, TidwellJ, CowellJK (2011) Src activation plays an important key role in lymphomagenesis induced by FGFR1 fusion kinases. Cancer research 71: 7312–7322.
75. Ren M, Qin H, Ren R, Cowell JK (2012) Ponatinib suppresses the development of myeloid and lymphoid malignancies associated with FGFR1 abnormalities. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, UK.
76. RicheldaR, RonchettiD, BaldiniL, CroL, ViggianoL, et al. (1997) A novel chromosomal translocation t(4; 14)(p16.3; q32) in multiple myeloma involves the fibroblast growth-factor receptor 3 gene. Blood 90: 4062–4070.
77. CrossNC, ReiterA (2008) Fibroblast growth factor receptor and platelet-derived growth factor receptor abnormalities in eosinophilic myeloproliferative disorders. Acta haematologica 119: 199–206.
78. SinghD, ChanJM, ZoppoliP, NiolaF, SullivanR, et al. (2012) Transforming fusions of FGFR and TACC genes in human glioblastoma. Science 337: 1231–1235.
79. WangP, DongQ, ZhangC, KuanPF, LiuY, et al. (2012) Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas. Oncogene 32: 3091–100.
80. MaisonneuveC, GuilleretI, VickP, WeberT, AndreP, et al. (2009) Bicaudal C, a novel regulator of Dvl signaling abutting RNA-processing bodies, controls cilia orientation and leftward flow. Development 136: 3019–3030.
81. PetiotA, ContiFJ, GroseR, RevestJM, Hodivala-DilkeKM, et al. (2003) A crucial role for Fgfr2-IIIb signalling in epidermal development and hair follicle patterning. Development 130: 5493–5501.
82. FengS, WangF, MatsubaraA, KanM, McKeehanWL (1997) Fibroblast growth factor receptor 2 limits and receptor 1 accelerates tumorigenicity of prostate epithelial cells. Cancer Res 57: 5369–5378.
83. RicolD, CappellenD, El MarjouA, Gil-Diez-de-MedinaS, GiraultJM, et al. (1999) Tumour suppressive properties of fibroblast growth factor receptor 2-IIIb in human bladder cancer. Oncogene 18: 7234–7243.
84. LorenziMV, CastagninoP, ChenQ, ChedidM, MikiT (1997) Ligand-independent activation of fibroblast growth factor receptor-2 by carboxyl terminal alterations. Oncogene 15: 817–826.
85. ChaseA, GrandFH, CrossNC (2007) Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome. Blood 110: 3729–3734.
86. GuagnanoV, KauffmannA, WohrleS, StammC, ItoM, et al. (2012) FGFR Genetic Alterations Predict for Sensitivity to NVP-BGJ398, a Selective Pan-FGFR Inhibitor. Cancer discovery 2: 1118–1133.
87. GozgitJM, WongMJ, MoranL, WardwellS, MohemmadQK, et al. (2012) Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models. Molecular cancer therapeutics 11: 690–699.
88. AmanoR, YamadaN, DoiY, YashiroM, OhiraM, et al. (2010) Significance of keratinocyte growth factor receptor in the proliferation of biliary tract cancer. Anticancer Res 30: 4115–4121.
89. KumarR, KnickVB, RudolphSK, JohnsonJH, CrosbyRM, et al. (2007) Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther 6: 2012–2021.
90. BallaroC, CeccarelliS, TiveronC, TatangeloL, SalvatoreAM, et al. (2005) Targeted expression of RALT in mouse skin inhibits epidermal growth factor receptor signalling and generates a Waved-like phenotype. EMBO reports 6: 755–761.
91. FerbyI, ReschkeM, KudlacekO, KnyazevP, PanteG, et al. (2006) Mig6 is a negative regulator of EGF receptor-mediated skin morphogenesis and tumor formation. Nature medicine 12: 568–573.
92. JeongJW, LeeHS, LeeKY, WhiteLD, BroaddusRR, et al. (2009) Mig-6 modulates uterine steroid hormone responsiveness and exhibits altered expression in endometrial disease. Proceedings of the National Academy of Sciences of the United States of America 106: 8677–8682.
93. LinCI, DuJ, ShenWT, WhangEE, DonnerDB, et al. (2011) Mitogen-inducible gene-6 is a multifunctional adaptor protein with tumor suppressor-like activity in papillary thyroid cancer. The Journal of clinical endocrinology and metabolism 96: E554–565.
94. ReschkeM, FerbyI, StepniakE, SeitzerN, HorstD, et al. (2010) Mitogen-inducible gene-6 is a negative regulator of epidermal growth factor receptor signaling in hepatocytes and human hepatocellular carcinoma. Hepatology 51: 1383–1390.
95. AnastasiS, FiorentinoL, FioriniM, FraioliR, SalaG, et al. (2003) Feedback inhibition by RALT controls signal output by the ErbB network. Oncogene 22: 4221–4234.
96. ZhangX, PickinKA, BoseR, JuraN, ColePA, et al. (2007) Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface. Nature 450: 741–744.
97. FrosiY, AnastasiS, BallaroC, VarsanoG, CastellaniL, et al. (2010) A two-tiered mechanism of EGFR inhibition by RALT/MIG6 via kinase suppression and receptor degradation. The Journal of cell biology 189: 557–571.
98. AnastasiS, SalaG, HuipingC, CapriniE, RussoG, et al. (2005) Loss of RALT/MIG-6 expression in ERBB2-amplified breast carcinomas enhances ErbB-2 oncogenic potency and favors resistance to Herceptin. Oncogene 24: 4540–4548.
99. DuncanCG, KillelaPJ, PayneCA, LampsonB, ChenWC, et al. (2010) Integrated genomic analyses identify ERRFI1 and TACC3 as glioblastoma-targeted genes. Oncotarget 1: 265–277.
100. YingH, ZhengH, ScottK, WiedemeyerR, YanH, et al. (2010) Mig-6 controls EGFR trafficking and suppresses gliomagenesis. Proceedings of the National Academy of Sciences of the United States of America 107: 6912–6917.
101. LiZ, DongQ, WangY, QuL, QiuX, et al. (2012) Downregulation of Mig-6 in nonsmall-cell lung cancer is associated with EGFR signaling. Molecular carcinogenesis 51: 522–534.
102. ZhangYW, StaalB, DykemaKJ, FurgeKA, Vande WoudeGF (2012) Cancer-type regulation of MIG-6 expression by inhibitors of methylation and histone deacetylation. PloS one 7: e38955.
103. ZhangYW, StaalB, SuY, SwiatekP, ZhaoP, et al. (2007) Evidence that MIG-6 is a tumor-suppressor gene. Oncogene 26: 269–276.
104. BaiA, MeetzeK, VoNY, KolliparaS, MazsaEK, et al. (2010) GP369, an FGFR2-IIIb-specific antibody, exhibits potent antitumor activity against human cancers driven by activated FGFR2 signaling. Cancer Res 70: 7630–7639.
105. ChristoforidesA, CarptenJD, WeissGJ, DemeureMJ, Von HoffDD, et al. (2013) Identification of somatic mutations in cancer through Bayesian-based analysis of sequenced genome pairs. BMC Genomics 14: 302.
106. KimD, SalzbergSL (2011) TopHat-Fusion: an algorithm for discovery of novel fusion transcripts. Genome Biol 12: R72.
107. IyerMK, ChinnaiyanAM, MaherCA (2011) ChimeraScan: a tool for identifying chimeric transcription in sequencing data. Bioinformatics 27: 2903–2904.
108. McPhersonA, HormozdiariF, ZayedA, GiulianyR, HaG, et al. (2011) deFuse: an algorithm for gene fusion discovery in tumor RNA-Seq data. PLoS Comput Biol 7: e1001138.
109. AsmannYW, HossainA, NecelaBM, MiddhaS, KalariKR, et al. (2011) A novel bioinformatics pipeline for identification and characterization of fusion transcripts in breast cancer and normal cell lines. Nucleic Acids Res 39: e100.
110. DiepCH, ZuckerKM, HostetterG, WatanabeA, HuC, et al. (2012) Down-regulation of Yes Associated Protein 1 expression reduces cell proliferation and clonogenicity of pancreatic cancer cells. PLoS One 7: e32783.
111. OngCK, SubimerbC, PairojkulC, WongkhamS, CutcutacheI, et al. (2012) Exome sequencing of liver fluke-associated cholangiocarcinoma. Nature genetics 44: 690–693.
112. BiankinAV, WaddellN, KassahnKS, GingrasMC, MuthuswamyLB, et al. (2012) Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 491: 399–405.
113. GuichardC, AmaddeoG, ImbeaudS, LadeiroY, PelletierL, et al. (2012) Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nature genetics 44: 694–698.